All In Biotech

Drug Trial Radar · NCT04944121

Phase 2 Study of RSLV-132 in Subjects With Long COVID

A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Post-acute COVID-19 (Long COVID)

Last checked: Nov 20, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Jun 25, 2021

Primary completion

Oct 31, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
Resolve TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome

Conditions

  • Post-acute Corona Virus 19 (COVID-19) (Long COVID)

Interventions

  • RSLV-132Drug

    10 mg/kg RSLV-132 administered by intravenous infusion

  • Sodium Chloride 0.9%Drug

    0.9% sodium chloride administered by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PROMIS Fatigue SF 7a T-scoreTime frame: From Baseline to Day 71

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Resolve Clinical Center

    Mobile, Alabama

  • Resolve Clinical Center

    Coral Gables, Florida

  • Resolve Clinical Center

    Pompano Beach, Florida

  • Resolve Clinical Center

    Knoxville, Tennessee

  • Resolve Clinical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.